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Summary
The antimicrobial activity of industrially important lactic acid bacteria as starter cultures
and probiotic bacteria is the main subject of this review. This activity has been attributed
to the production of metabolites such as organic acids (lactic and acetic acid), hydrogen
peroxide, ethanol, diacetyl, acetaldehyde, acetoine, carbon dioxide, reuterin, reutericyclin
and bacteriocins. The potential of using bacteriocins of lactic acid bacteria, primarily used
as biopreservatives, represents a perspective, alternative antimicrobial strategy for continu-
ously increasing problem with antibiotic resistance. Another strategy in resolving this pro-
blem is an application of probiotics for different gastrointestinal and urogenital infection
therapies.
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Introduction
Lactic acid bacteria (LAB) are Gram-positive, non-
-spore forming, catalase-negative bacteria that are de-
void of cytochromes and are of nonaerobic habit but are
aero-tolerant, fastidious, acid tolerant and strictly fer-
mentative; lactic acid is the major end-product of sugar
fermentation (1). They are the most widely used bacteria
as starter cultures for the industrial processing of fer-
mented dairy, meat, vegetable and cereal products. De-
spite the starter culture addition, non-starter lactic acid
bacteria (NSLAB), originating from the raw material and
environment, grow out during fermentation and may
reach higher numbers than the starters. Reduction of pH
and conversion of sugars to organic acids are the prima-
ry preserving actions that these bacteria provide to fer-
mented food. However, many kinds of food are still fer-
mented naturally, without the use of starter cultures, by
autochthonous lactic acid bacteria, which form the charac-
teristic properties of the products. These natural isolates
of lactic acid bacteria from spontaneous fermentations
could be used as specific starter cultures or as adjunct
strains, after phenotypic and genotypic characterisation,
and they represent a possible source of potentially new
antimicrobial metabolites (2–4). In addition, the applica-
tion of lactic acid bacteria and their antimicrobial meta-
bolites in the prevention of food spoilage and the extension
of the shelf life of food that is ready to eat, fresh-tasting,
nutrient and vitamin rich, minimally processed and bio-
preserved are the major challenges for the current food
industry (5). The use of bacteriocin-producing lactic acid
bacteria as protective strains or bacteriocins in form of
purified or concentrated compounds as biopreservatives
to control undesirable bacteria remains a primary focus
of researches related to food safety and quality (6).
In the concept of functional food, especially in dairy
industry, there is an increasing interest for probiotic
products that contain lactic acid bacteria of intestinal
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origin. Probiotic lactic acid bacterial strains must be
chosen according to accurate selection criteria in order
to survive the transition through gastrointestinal tract and
preferably colonize the intestinal tract for a sufficiently
long period to achieve the desired healthy effect (7). One
of the most important properties of probiotics is protec-
tion against pathogens in the intestinal tract of the host.
The role of antimicrobial compounds produced by pro-
biotic strains as prophylactic agents against enteric in-
fections is crucial and well documented (8–10).
The antimicrobial activity of starter cultures and
probiotic bacteria has been attributed to the production
of metabolites such as organic acids (lactic and acetic acid),
hydrogen peroxide, ethanol, diacetyl, acetaldehyde, other
low molecular mass compounds with antimicrobial acti-
vity and bacteriocins (11,12). Industrial potential of anti-
microbials from lactic acid bacteria is illustrated in Fig. 1.
Antimicrobials from Lactic Acid Bacteria
Antimicrobial substances produced by lactic acid bac-
teria can be divided into two main groups: low mole-
cular mass substances with molecular mass <1000 Da
and high molecular mass substances with molecular
mass >1000 Da, such as bacteriocins. All non-bacteriocin
antimicrobial substances from LAB are of low molecular
mass (13).
Low molecular mass antimicrobials
The metabolites of LAB with antimicrobial activity
are accumulated in their environment at the levels and
proportions that depend on the species of LAB and chem-
ical composition of the growth media. Fermentation of
hexoses by lactic acid bacteria is characterized by homo-
fermentative production of lactic acid or by heterofer-
mentative production of equimolar amounts of lactate,
acetate/ethanol and carbon dioxide. Pentoses are ferment-
ed by many heterofermentative and homofermentative
LAB in the same way since phosphoketolase of homo-
fermentative LAB is generally inducible by pentoses. Fer-
mentation of pentoses yields the equimolar amounts of
lactic and acetic acid.
Most of heterofermentative species have flavoprotein
oxidases, which catalyse the reduction of oxygen, result-
ing in the accumulation of hydrogen peroxide. During
heterofermentations, products such as formic acid, acet-
oin, acetaldehyde and diacetyl, which possess antimicrob-
ial activity, can be accumulated. Malic, lactic and citric
acid can be further metabolised to other antimicrobial
products such as acetic acid, formic acid and CO2 (14).
The main low molecular mass metabolites of LAB and
their antimicrobial spectra are shown in Table 1 (11,14–19).
Organic acids
The most important and best characterised antimi-
crobials produced by LAB are lactic and acetic acid. The
amount and type of acids produced during fermentation
influence the subsequent microbial activity in the fer-
mented material. Acetic acid, for example, is more anta-
gonistic against yeasts compared to lactic acid. Some
oxidative yeasts are able to utilize organic acids as a car-
bon and energy source and consequently cause spoilage
through deacidification in fermented, especially plant
material where they are naturally present (20). The in-
hibitory effect of organic acids is mainly caused by un-
dissociated form of the molecule, which diffuses across
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Fig. 1. Industrial potential of antimicrobials from lactic acid bacteria
the cell membrane towards the more alkaline cytosol and
interferes with essential metabolic functions. The toxic
effects of lactic and acetic acid include the reduction of
intracellular pH and dissipation of the membrane poten-
tial (15,19).
Hydrogen peroxide
Antimicrobial activity of hydrogen peroxide is attri-
buted to its strong oxidizing effect on the bacterial cell
and to the destruction of basic molecular structures of
cell proteins (14). In raw milk, hydrogen peroxide pro-
duced by lactic acid bacteria can, after being catalysed
by lactoperoxidase, oxidise endogenous thiocyanate. The
oxidized intermediary products are toxic to different bac-
teria (16). Hydrogen peroxide production has been con-
sidered as the main metabolite of LAB that could protect
against urogenital infections, especially in the case of bac-
terial vaginosis (21).
Diacetyl, acetaldehyde and acetoin
Heterofermentative LAB produce active acetaldehyde
by decarboxylation of pyruvate. This product then con-
denses with pyruvate, forming a-acetolactate and it is
converted by a-acetolactate synthases to diacetyl. The pro-
duct of decarboxylation of a-acetolactate and reduction
of diacetyl is acetoin (13,22). Diacetyl (2,3-butanedione)
is best known for the buttery aroma that it imparts to
fermented dairy products, but this property as well as
high concentration needed to provide preservation of food
limit the use of diacetyl as food preservative. Similarly,
an acetaldehyde, usually present in fermented dairy pro-
ducts in concentrations smaller than necessary for inhi-
bition of undesired microorganisms, also plays a role in
controlling the growth of contaminants, together with other
antimicrobial metabolites of lactic acid bacteria (11).
Carbon dioxide
The influence of carbon dioxide on product preser-
vation is twofold. Namely, except for its own antimicro-
bial activity, it creates an anaerobic environment by re-
placing the existent molecular oxygen. The antifungal
activity of CO2 is due to the inhibition of enzymatic de-
carboxylations and to its accumulation in the membrane
lipid bilayer resulting in dysfunction in permeability (14).
Reuterin and reutericyclin
Selected isolates of Lactobacillus reuteri produce two
compounds, reuterin and reutericyclin, both active to-
wards Gram-positive bacteria. Reutericyclin is a tetramic
acid derivative and reuterin is a mixture of monomeric,
hydrated monomeric and cyclic dimeric forms of b-hy-
droxypropionaldehyde with a broader spectrum of inhi-
bitory activity, including Gram-negative bacteria, fungi
and protozoa (23–25).
Other low molecular mass antimicrobials
Other low molecular mass compounds with antimi-
crobial activity against Gram-positive and Gram-nega-
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Table 1. Low molecular mass antimicrobial metabolites of lactic acid bacteria (11,14–19)
Compound Microorganisms producers Antimicrobial spectrum
lactic acid all lactic acid bacteria yeasts
Gram-positive bacteria
Gram-negative bacteria






variety of genera of lactic acid bacteria including:




hydrogen peroxide all lactic acid bacteria yeasts
Gram-positive bacteria
Gram-negative bacteria
carbon dioxide heterofermentative lactic acid bacteria most of the taxonomic groups
of microorganisms
reuterin Lactobacillus reuteri fungi, protozoa, Gram-positive
and Gram-negative bacteria
reutericyclin Lactobacillus reuteri Gram-positive bacteria





Lactobacillus plantarum, Lactobacillus alimentarius,
Lactobacillus rhamnosus, Lactobacillus sanfranciscensis,
Lactobacillus hilgardii, Leuconostoc citreum, Lactobacillus brevis,
Lactobacillus acidophilus, Leuconostoc mesenteroides
fungi






tive bacteria, moulds and yeasts have been described,
including antifungal cyclic dipeptides, phenyllactic acid,
4-hydroxyphenyllactic acid and 3-hydroxy fatty acids
(26–28). Niku-Paavola et al. (29) discovered new types of
antimicrobial compounds produced by Lactobacillus plan-
tarum (benzoic acid, methylhydantoin and mevalonolac-
tone) active against fungi and some Gram-negative bac-
teria.
Bacteriocins of lactic acid bacteria
Some of LAB produce bacteriocins, antibacterial pro-
teinaceous substances with bactericidal activity against
related species (narrow spectrum) or across genera (broad
spectrum of activity) (30,31). Bacteriocin biosynthesis is
a desirable characteristic for strain selection as it serves
as an important mechanism of pathogen exclusion in fer-
mented foods as well as in the gastrointestinal environ-
ment.
Bacteriocins are ribosomally synthesized peptides or
proteins with antimicrobial activity produced by many
Gram-positive and Gram-negative bacteria; however, those
produced by food grade LAB have received consider-
able attention due to their potential application in food
industry as natural preservatives (biopreservatives). LAB
bacteriocins are small antimicrobial peptides or proteins
that possess activity towards closely related Gram-posi-
tive bacteria, whereas producer cells are immune to their
own bacteriocins (32–34). There are several proposed
bacteriocin classifications divided into 3 or 4 classes: (i)
lantibiotics or small, heat-stable, lanthionine-containing,
single- and two-peptide bacteriocins (class I), whose bio-
logically inactive prepeptides are subjected to extensive
post-translational modification; (ii) small, heat-stable, non-
-lanthionine-containing bacteriocins (class II), including
pediocins like or Listeria-active bacteriocins (class IIa), two-
-peptide bacteriocins (class IIb) and circular bacteriocins
(class IIc); and (iii) bacteriolysins or large, heat-labile, ly-
tic proteins, often murein hydrolases (class III) (31,32,
35). Some authors (36,37) also proposed (iv) class IV bac-
teriocins that require non-proteinaceous moieties (lipid,
carbohydrate) for their activity (Table 2, 31,35–37).
Lantibiotics are small (<5 kDa) peptides containing
unusual amino acids lanthionine, dehydroalanine, a-de-
hydroalanine and dehydrobutirine. According to their
chemical structures and mode of action, they are sub-
divided into type A and type B lantibiotics (34,38,39).
Type A lantibiotics are elongated amphiphilic lantibio-
tics, like nisin, with a net positive charge, which are
active through the formation of pores in bacterial mem-
branes, leading to the dissipation of membrane poten-
tial. Type B lantibiotics are smaller globular peptides, like
mersacidin, which have negative or no net charge, and
act through the inhibition of specific enzymes (31,34,40).
Class II encompasses the more common non-lanthio-
nine-containing bacteriocins, which are non-modified,
small (<10 kDa), heat stable peptides. Representatives
belonging to this heterogeneous group of bacteriocins are
divided into 3 subgroups. Class IIa includes pediocin-
-like peptides having an N-terminal consensus sequence
–Tyr-Gly-Asn-Gly-Val-Xaa-Cys. Pediocin-like peptides
have attracted much attention due to their specific activ-
ity against food pathogen Listeria monocytogenes (41).
Class IIb contains bacteriocins requiring two different
peptides for their activity, and class IIc contains the re-
maining peptides of the class, including sec-dependent
bacteriocins (34). Class III bacteriocins (bacteriolysins) are
large (>30 kDa), heat-labile antimicrobial proteins not as
well characterised, whose mechanism of action is dis-
tinct in function as they lyse the sensitive cells by cata-
lysing cell-wall hydrolysis (31). Only four LAB bacterio-
lysins have been genetically characterised so far (42–44),
although the non-LAB bacteriolysins have been identi-
fied.
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Table 2. Classification, major characteristics and some examples of bacteriocins (31,35–37)






small (<5 kDa) membrane-active peptides
containing unusual amino acids
– elongated peptides with a net positive charge
– smaller globular peptide with negative or no
net charge
type A:













IIc: with wide range of effects on membrane
permeability and cell wall formation
IIa: pediocin PA1, sakacin A,
sakacin P, leucocin A, curvacin A
IIb: lactococcin G, lactococcin M,
lactacin F, plantaricin A
IIc: acidocin B, enterocin P, enterocin B,
reuterin 6
Class III
bacteriolysins large (>30 kDa) heat-labile antimicrobial proteins
complex proteins with domain-type structure
that function through the lyses of sensitive cells
by catalysing cell wall hydrolysis
lysostaphin, enterolysin A,
helveticin J, helveticin V-1829
Class IV
complex bacteriocins carrying lipid or
carbohydrate moieties
plantaricin S, leuconocin S,
lactocin 27, pediocin SJ1
Class IV of complex bacteriocins that require non-
-proteinaceous moieties like carbohydrate or lipid for
their activity has also been suggested by some authors
(36); however, bacteriocins in this class have not been
characterised convincingly, hence definition of this class
requires additional characterisation (31,34).
Mode of bacteriocin action
Bacteriocins that are produced by LAB can be of
broad or narrow spectrum, but in general, the activity is
directed against low G+C Gram-positive species (31).
The antibacterial spectrum includes spoilage organisms
and foodborne pathogens such as Listeria monocytogenes
and Staphylococcus aureus. Wide ranges of mode of ac-
tion have been described for bacteriocins, such as en-
zyme activity modulation, inhibition of outgrowth of
spores and formation of pores in cell membrane. Most
bacteriocins interact with anionic lipids that are abun-
dantly present in the membranes, and consequently ini-
tiate the formation of pores in the membranes of sus-
ceptible cells (34,38). However, generalised membrane
disruption models cannot adequately describe the mode
of action of bacteriocins. Rather, specific targets seem to
be involved in pore formation and other activities. For
the nisin and epidermin family of lantibiotics, the mem-
brane-bound cell wall precursor lipid II has been iden-
tified as target (45). Most of class II bacteriocins dissi-
pate the proton motive force (PMF) of the target cell via
pore formation (46). The subclass IIa bacteriocin activity
depends on a mannose permease of the phosphotrans-
ferase system (PTS) as a specific target. The subclass IIb
bacteriocins (two-component) also induce dissipation of
the PMF by forming cation- or anion-specific pores;
specific targets have not yet been identified. Finally,
subclass IIc comprises miscellaneous peptides with va-
rious modes of action such as membrane permeabilisa-
tion, specific inhibition of septum formation and phero-
mone activity (31).
Resistance and immunity to bacteriocins
Bacteriocin producer has developed protection mecha-
nisms against its own bacteriocin. Two distinct systems
of bacteriocin immunity in the producing cell have been
identified. Protection can be mediated by dedicated
immunity protein and/or a specialised ABC-transporter
system involving two or three subunits that probably
pump the bacteriocin through the producer membrane.
These two immunity systems can work synergistically to
protect the producing cells from their own bacteriocin
(47). In the case of lantibiotic immunity, e.g. protein
LanI, which is most likely localised at the cytoplasmic
membrane, probably confers immunity to the producer
cell by preventing pore formation by the bacteriocin.
Related ABC-transporter system LanEFG probably acts
by excreting bacteriocins that were inserted into the
membrane back to the extracellular microenvironment
and thus keeping bacteriocin concentration in the mem-
brane under a critical level (35,38). Regulation of bac-
teriocin production and immunity is most frequently
mediated through two-component signal-transduction
systems, often as part of the quorum-sensing mecha-
nism (48).
Bacteriocin-Producing Starter and Non-Starter
Lactic Acid Bacteria in Food Industry
Besides the well-known biopreservative effects of
antimicrobial metabolites of lactic acid bacteria such as
lactic acid, acetic acid, hydrogen peroxide and diacetyl,
bacteriocins have the most immediate potential in food
application as biopreservatives and they can be readily
introduced into food without any concentration or puri-
fication (31). Since lactic acid bacteria are generally re-
garded as safe (GRAS) according to the FDA, they could
be used in food production and food biopreservation.
Bacteriocin-producing starter cultures
The main antimicrobial effect of starter LAB, re-
sponsible for biopreservation, is the rate of acidification,
but in slightly acidified products or to eliminate unde-
sirable microorganisms that display acid tolerance, such
as Listeria monocytogenes, the bacteriocinogenic activity
could play a crucial role. The use of bacteriocin-produc-
ing starter cultures may not only contribute to food safety,
but also prevent the growth of undesirable autochtho-
nous lactic acid bacteria that produce off-flavour. This
property may improve the competitiveness of the starter
cultures and lead to a more controlled and standardized
fermentation process as it has been shown in sourdough,
fermented sausage, fermented vegetables and olives, and
cheese production (25,49–51).
Bacteriocin-producing adjunct cultures
Bacteriocin producers can be delivered to a food pro-
duct as an adjunct culture, together with the starter cul-
ture. In this case, the ability of starter adjunct to grow
and produce bacteriocin in the product is crucial for its
successful use. The bacteriocin-producing adjunct cul-
tures are mostly isolated from raw milk, vegetables,
cereals and other natural sources of lactic acid bacteria
that are believed to contain strains essential not only for
the characteristic flavour of traditional fermented pro-
ducts, but also with promising and useful properties
such as bacteriocinogenic activity, which will make them
applicable as starters. For example, Lactococcus lactis
strain, which produces both nisin and lacticin 481, iso-
lated from raw ewe’s milk, might be used as adjunct
culture to the commercial starter in the manufacture of
dairy products to inhibit or destroy undesired micro-
organisms (52). Adjunct culture does not need to con-
tribute to the flavour but it is important that the starter
culture is resistant to bacteriocin produced by the ad-
junct culture. One of the exceptions is the controlled
lysis of starter culture during cheese manufacture caused
by bacteriocin-producing strain, with the aim to release
intracellular enzymes, needed for accelerated ripening
and improvement of product flavour (31,53).
Bacteriocin-producing protective cultures
Bacteriocinogenic protective cultures alone can be
used to inhibit spoilage and pathogenic bacteria during
the shelf life of non-fermented foods by producing bac-
teriocin in situ or previously cultured in growth medium
and after that applied as an ingredient in food pro-
cessing. Two preparations are already present on the
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market: ALTATM 2341, containing pediocin PA1 pro-
duced by Pediococcus acidilactici, and MicrogardTM, a
commercially available fermented milk product contain-
ing antimicrobial metabolites. In the literature different
milk-based preparations such as lacticin 3147 are de-
scribed (54). The addition of purified or semi-purified
bacteriocins as food preservatives requires approval from
legislative point of view. There is also a problem of cost-
ly production because of low production rates, instabil-
ity and expensive downstream processing of bacterio-
cins. If immobilized or microencapsulated bacteriocin or
bacteriocinogenic strain is applied on the food surface,
much lower concentration is needed compared to the
application in the whole food volume (5,55). Other ad-
vantages of immobilized bacteriocins are the possibility
of gradient-dependent, continuous supply of bacteriocin
and the protection against food components and enzy-
matic inactivation. The use of antimicrobial films con-
taining immobilized bacteriocins for the development of
antimicrobial packaging is a recently developed tech-
nique (56,57).
Use of bacteriocins in combination with other
antimicrobial factors
The antimicrobial spectra and activity of bacterio-
cins can be extended through the synergy between dif-
ferent antimicrobial factors such as inorganic salts (espe-
cially sodium chloride), organic acids and their salts,
chelating agents (such as EDTA), essential oils and their
active components, phenolic compounds, as well as other
natural antimicrobials. Application of bacteriocins together
with different physicochemical treatments, like heat treat-
ment, modified atmosphere packaging, high hydrostatic
pressure, pulsed electric field, pulsed magnetic field and
gamma irradiation, has received great attention in recent
years (5,34,58,59). The effectiveness of bacteriocins in com-
bination with hurdle technology will depend on the type
of food and its natural microflora. Thus with acidifica-
tion of the food acidotolerant bacteria may be selected,
while heat treatment may favour bacterial endospores,
but in combination with bacteriocins higher sensitiza-
tion may be achieved after optimization of doses and
conditions. Furthermore, the Gram-negative bacteria could
become sensitive to bacteriocin activity upon exposure
to hurdles such as chelating agents that destabilize the
bacterial outer membrane (5,60–62).
Application of nisin, the most famous bacteriocin,
in food industry
So far, nisin is the only bacteriocin licensed as food
preservative (E234). Commercial production of nisin by
Lactococcus lactis ssp. lactis began in England in 1953,
and international acceptance of nisin was given in 1969
by the Joint Food and Agriculture Organisation/World
Health Organization (FAO/WHO) (63). In 1988, it was
approved by the US Food and Drug Administration (US
FDA) for use in pasteurized, processed cheese spreads
and since then, as a food additive in over 50 countries
(31). Nowadays, the most established available form of
nisin for use as a food preservative is NisaplinTM. Appli-
cations of nisin have been developed for processed cheese,
dairy desserts, milk, fermented beverages, bacon, frank-
furters and fish, often in combination with hurdle tech-
nologies to achieve better inhibitory effect (11,54,64–66).
Its use extends shelf life of the food by inhibition of
Gram-positive spoilage bacteria such as Listeria, Staphy-
lococcus and Mycobacterium, and spore-forming bacteria
Bacillus and Clostridium (67–71). The spores of these bac-
teria are more sensitive to nisin than their vegetative
cells, so nisin is often applied in heat-processed food
such as canned vegetables. The spectrum of its activity
can be successfully broadened when it is applied in
combination with chelating agent such as EDTA (72,73).
Very few variants of six naturally occurring nisin mole-
cules are described with enhanced activity against Gram-
-positive pathogens (74).
The Role of Antimicrobial Activity of
Probiotic Lactic Acid Bacteria in Prevention
and Treatment of Infections
The widespread use of antibiotics in treatment of in-
fections resulted in increased number of antibiotic resist-
ant bacteria, fewer treatment options and most anti-
biotics ineffective (75). Alternative antimicrobial strategies
in the treatment and prevention of gastrointestinal in-
fections are the application of probiotics and their anti-
microbial metabolites such as bacteriocins. Probiotic is a
mono- or mixed culture of live microorganisms which,
applied to animal or man, affect beneficially the host by
improving the properties of the indigenous microflora,
according to broader Fuller’s definition (76), proposed
by Havenaar and Huis in’t Veld (77). Recently, probio-
tics have been defined as 'live microorganisms which
when administered in adequate amounts confer a health
benefit on the host' (63). Probiotics are largely adminis-
tered through functional foods and as dietary supple-
ments (pharmaceuticals) or biotherapeutics (approved
drugs with important therapeutic applications) (78). Lac-
tic acid bacteria are the most important probiotic micro-
organisms because they are autochthonous in the human
gastrointestinal tract of healthy people (79,80). A consid-
erable number of health benefits have been postulated
as a result of the probiotic intake, including modifica-
tion of gut microflora, prevention of pathogen colonisa-
tion, stimulation of gut immunity, reduction in inflam-
matory reactions, prevention of colon cancer, alleviation
of lactose intolerance, lowering of serum cholesterol and
reduction of food allergies (7,81). Each property is strain-
-dependent, and must be confirmed by in vitro experi-
ments, animal experiments and clinical trials. Mode of
action of probiotics includes antagonistic effects against
pathogenic microorganisms in intestinal tract (embracing
multiple mechanisms for preventing infection), alteration
of microbial metabolism in the intestinal tract, stimula-
tion of immunity and increase of nutritional value of food.
Much of the benefit derived from probiotic LAB is a
consequence of their ability to acidify the intestine by
producing the lactic acid and thus create a hostile en-
vironment for pathogens. Besides lactic acid, probiotic
bacteria can also produce antimicrobials such as hydro-
gen peroxide, bacteriocins, short-chain fatty acids such
as acetic, propionic and butyric acid, rendering vital nu-
trients unavailable to pathogens and altering the redox
potential of the intestinal environment. There is also
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considerable evidence that deconjugation of conjugated
bile salts in the intestine is the mechanism of the resis-
tance of probiotic bacteria to high concentration of bile
salts in small intestine, which are inhibitory for Gram-
-positive bacteria, but have little effect against Gram-ne-
gative bacteria. However, upon deconjugation, the free
bile acids are more toxic for both, Gram-positive and
Gram-negative microorganisms, which is also one of the
antagonistic mechanisms against pathogens in the intes-
tine (82–85).
Another line of probiotic defence against infection
in the intestinal tract is the enhancement of intestinal
barrier function by the promotion of mucin production
and by colonisation resistance mechanism, which pre-
vents colonisation of the intestine by pathogens (10).
Colonization resistance is apparent in two major regions
of the intestinal habitat: the luminal contents and the
mucosal surfaces. In the luminal contents, the most im-
portant resistance mechanism is the production of anta-
gonistic metabolites by probiotic or autochthonous bene-
ficial bacteria that suppress multiplication of pathogens.
Competition for nutrients present in limited quantities
in the intestine is another mechanism that regulates
populations of the established intestinal microflora. At
the mucosal surfaces, the resistance mechanism of prime
importance is the occupation of adhesive sites. Although
the composition of the intestinal microflora is rather
stable in healthy individuals and described mechanisms
effectively impede colonization by pathogens, these harm-
ful microorganisms become impaired when intestinal
microflora is disturbed by endogenous and exogenous
stress factors (7,86).
Adherence factors on the surface of probiotic cells,
mostly proteins or polysaccharides, may promote patho-
gen exclusion, mucosal integrity and host immunomo-
dulation. Comparative genome analyses confirmed the
role of mucus-binding proteins (Mub) in intestinal mu-
cus adherence of Lactobacillus strains isolated from the
intestine. Namely, the MUB domains found exclusively
in intestinal lactobacilli suggest that these proteins me-
diate specific interactions or functions between these mi-
crobes and their hosts (87,88). Cell surface structures such
as teichoic acids, lipoteichoic acids and surface layer pro-
teins (S-layers) have also been reported as important for
probiotic adhesion and immunomodulation. S-layer pro-
teins from different strains of L. acidophilus, L. helveticus,
L. brevis, L. kefir and L. crispatus have been shown to be
involved in mediating adhesion to different host sur-
faces (89–92). Additionally, some of them are found to
prevent adhesion of the foodborne pathogens, such as
Escherichia coli and Salmonella enterica serovar Typhimu-
rium, to cultured intestinal epithelial cell lines, to frozen
sections of intestinal tissue, as well as to intestinal mu-
cus and uroepithelial cells (84,93–97). Surface proteins
have also been characterised as key factors involved in
immunomodulation (98–100). Not only LAB themselves
were reported to activate immune cells and to confer en-
hanced protection against enteropathogens (61,101–104).
Non-bacterial fractions of fermented milk, containing
bacterial metabolites produced during fermentation by
LAB, were effective in induction of different cytokine
patterns and enhanced protection against enteropatho-
gens in mice (105–107).
The mechanisms behind the prevention of gastroin-
testinal and urinary tract infections by probiotic bacteria
have been elucidated in animal, but also in human stud-
ies, confirming enhancement of immune responses and
production of antimicrobial substances (11,97,108–111).
However, there is increasing clinical evidence that pro-
biotics are effective not only in the treatment and pre-
vention of gastrointestinal diseases, but also in chronic
liver disease, multiple organ dysfunction syndrome and
autoimmune disease (87,112–114).
Probiotic Lactic Acid Bacteria and Bacteriocins
in Human and Veterinary Medicine
The overuse and misuse of antibiotics in humans,
veterinary and agriculture practices causes the spread of
numbers of community- and hospital-acquired infec-
tions produced by bacterial strains resistant to single
and multiple antimicrobial drugs (115). This situation
and the already imposed prohibitions of the use of anti-
biotics as growth promoters for farm animals have drawn
attention to possible alternatives. The application of pro-
biotic cells and competitive exclusion preparations of
lactic acid bacteria in human and veterinary prophy-
lactic and curing therapy is one of the alternatives. The
administration of bacteria that produce antimicrobial
substances, especially bacteriocins, is more cost-effective
approach than the application of pure antimicrobials.
There are numerous probiotic products on the market
with various health claims, mostly for treatment of anti-
biotic or travel diarrhoea and for the balance of intest-
inal or vaginal microflora of humans. All of these pro-
ducts are considered food supplements, not drugs. How-
ever, a new generation of probiotics, considered living
drugs, will be tailor-made for different gastrointestinal
and urogenital disease therapies or as delivery systems
for vaccines, immunoglobulins and other protein-based
therapies. Some of the finished and ongoing studies,
based on genomic, proteomic and metabolomic research,
are promising in evaluation of specific probiotics as
drugs for prevention and treatment of infections and
other diseases (21,74,78,87,97,113).
There are also a lot of nutritional additives with
probiotic bacteria for farm animals already in use or
have been proposed as means to reduce or eliminate
pathogens or as a means to improve growth and feed
conversion (116). In addition, agents such as bacteriocins
have been studied or proposed as potential human and
animal therapeutics because they are considered more
natural than the currently used antibiotics and are pro-
duced by GRAS lactic acid bacteria. Although Gram-ne-
gative bacteria do not represent target cells for bacterio-
cins, additions of chelating agents such as EDTA and
detergents such as Tween 80 can broaden their antimi-
crobial spectrum (117). The best studied lantibiotic, nisin,
has a potential in treatment of peptic ulcer disease by
inhibiting Helicobacter pylori (118). The possible therapeu-
tic use of nisin was proposed by Brumfitt et al. (119) in
combination with peptidoglycan-modulating antibiotics
and confirmed its activity against MRSA (methicillin-re-
sistant Staphylococcus aureus) and VRE (vancomycin-re-
sistant enterococci). Giacometti et al. (120) proposed the
use of nisin in combination with polymycin E or clari-
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thromycin against infection caused by Pseudomonas aeru-
ginosa. After the treatment of catheters and tracheotomy
tubes with nisin, Gram-positive bacteria were inhibited
(121), while Severina et al. (122) obtained the inhibition
of multidrug resistant pathogens such as Staphylococcus and
Streptococcus strains by nisin. Development of novel bac-
teriocin-based drugs, aimed at potential target cells, both
prokaryotic and eukaryotic, offers the possibility to de-
sign improved antibiotics with refined characteristics (123).
The company Biosynexus (Gaithersburg, MD, USA) has
developed a topical antibiotic preparation with nisin as
one of the active components for skin infection treat-
ment. Furthermore, the company also has a product
containing bacteriolysin lysostaphin, a large bacteriolytic
protein active against antibiotic-sensitive as well as anti-
biotic-resistant Staphylococcus aureus. Both products are
focused on the prevention and treatment of multidrug-
-resistant staphylococcal infections in humans. There are
also two commercial preparations of nisin for veterinary
medicine, effective in the prevention and treatment of
mastitis, produced by ImmuCell Corporation (Portland,
ME, USA), Wipe Out® and Mast Out® (124). The efficacy
of nisin Z in the treatment of bovine subclinical mastitis,
especially against drug-resistant S. aureus-caused intra-
mammary infections, was evaluated by Wu et al. (125).
Furthermore, two-peptide bacteriocin lacticin 3147, pro-
duced by Lactococcus lactis, showed potential in the pre-
vention of infectious diseases such as bovine mastitis
caused by staphylococci and streptococci (126,127). This
bacteriocin is also used as an active agent in Pfizer
Animal Health (Pfizer Inc, New York, NY, USA) product
under the name Orbeseal Teat Sealant for the prevention
of intramammary infections throughout the dry cow pe-
riod (128). Furthermore, there is an example how patho-
genic bacteriocin-producing strain Streptococcus mutans,
a causative of dental caries, could be used for the the-
rapy after genetic modification in order to lose its patho-
genicity and ability to produce lactic acid, but still can
colonize the oral cavity and produce mutacin, a bacte-
riocin active against pathogenic strains (129). Nowadays,
protein engineering enables improved stability and solu-
bility of nisin at physiological pH, important for its use
in human therapy (130). The Nisin-Controled Expression
(NICE) system in Lactococcus lactis is one of the best cha-
racterized expression systems that can be upregulated
more than 1000-fold with the addition of nisin (131).
Induction with NICE system could be used for the ex-
pression of heterologous proteins in Lactococcus lactis.
Good example is the expression of E7 antigen from
human papilloma virus type-16 (HPV-16) on the cell
wall of Lactococcus lactis (132). The capacity of different
strains of LAB to produce heterologous antigens, either
intracellularly, extracellularly or cell wall-attached, has
been clearly demonstrated and makes them potential
candidates for the development of new safe mucosal
vaccines. Among them, Lactococcus lactis, as the model
lactic acid bacterium, is the most frequently used as live
vaccine delivery vector (131). Current methodologies and
techniques for genetic manipulations of LAB allow pro-
gress and development of novel vaccine production and
types of vaccinations using LAB and their bacteriocin
expression systems.
Concluding Remarks
The potential of using bacteriocins of lactic acid bac-
teria, primarily used as biopreservatives, represents a per-
spective, alternative antimicrobial strategy against the
continuously increasing problem of antibiotic resistance.
Another strategy in resolving this problem is an appli-
cation of probiotics in prophylaxis and therapy of differ-
ent gastrointestinal and urogenital infections. Charac-
terization of lactic acid bacteria and their beneficial
mechanisms allows progress in their use in the food in-
dustry and their potential in promoting human and
animal health and nutrition.
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